Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Author:
Open Access
- 31 May 2013
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 22 (128) , 163-168
Abstract
Recently updated guidelines have provided revised recommendations, based on the GRADE criteria, for the diagnosis and pharmacological and non-pharmacological management of patients with idiopathic pulmonary fibrosis (IPF). Cochrane reviews are also a highly respected and reliable source of evidence-based information that identify and analyse all available data of overall treatment effects from appropriate studies. A recent update of one Cochrane review failed to identify any new evidence supporting the use of corticosteroids in IPF. Another review of data from 15 randomised controlled studies of non-steroid agents for the treatment of IPF identified two trials of interferon-γ-1b suitable for analysis. However, the pooled analysis revealed no treatment effect in terms of survival. A further meta-analysis of three phase III studies of pirfenidone treatment in IPF patients suggested a significant increase in progression-free survival. The interpretation of recent international and national European guideline updates and treatment recommendations, available clinical data from published and ongoing trials investigating potential pharmacological agents, and the individual patient's preferences, must be considered in the clinical management of this disease.Keywords
This publication has 21 references indexed in Scilit:
- S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen LungenfibrosePneumologie, 2013
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialThe Lancet, 2009
- High-Dose Acetylcysteine in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2005
- Antioxidant Therapy for Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2005
- A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2004
- Idiopathic Pulmonary Fibrosis: Predicting Response to Therapy and SurvivalAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Systematic Reviews: Rationale for systematic reviewsBMJ, 1994